Tony W Ho is Executive VP, Head of R&D of CRISPR Therapeutics AG. Currently has a direct ownership of 52,364 shares of CRSP, which is worth approximately $2.42 Million. The most recent transaction as insider was on Dec 06, 2021, when has been sold 12,607 shares (Common Shares) at a price of $69.17 per share, resulting in proceeds of $872,026. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 52.4K
0% 3M change
0% 12M change
Total Value Held $2.42 Million

Tony W Ho Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 06 2021
SELL
Payment of exercise price or tax liability
$872,026 $69.17 p/Share
12,607 Reduced 19.4%
52,364 Common Shares
Dec 03 2021
BUY
Exercise of conversion of derivative security
-
26,667 Added 29.1%
64,971 Common Shares
Mar 10 2021
SELL
Payment of exercise price or tax liability
$265,805 $124.15 p/Share
2,141 Reduced 5.29%
38,304 Common Shares
Mar 10 2021
BUY
Exercise of conversion of derivative security
-
4,583 Added 10.18%
40,445 Common Shares
Mar 05 2021
SELL
Payment of exercise price or tax liability
$181,720 $114.65 p/Share
1,585 Reduced 4.23%
35,862 Common Shares
Mar 05 2021
BUY
Exercise of conversion of derivative security
-
3,333 Added 8.17%
37,447 Common Shares
Dec 21 2020
SELL
Open market or private sale
$3,525,349 $149.69 p/Share
23,551 Reduced 40.95%
33,964 Common Shares
Dec 21 2020
BUY
Exercise of conversion of derivative security
$398,012 $16.9 p/Share
23,551 Added 29.05%
57,515 Common Shares
Jun 23 2020
SELL
Open market or private sale
$521,061 $75.2 p/Share
6,929 Reduced 17.03%
33,747 Common Shares
Jun 22 2020
SELL
Open market or private sale
$16,062 $70.14 p/Share
229 Reduced 0.56%
40,676 Common Shares
May 26 2020
SELL
Open market or private sale
$427,854 $70.14 p/Share
6,100 Reduced 12.98%
40,905 Common Shares
May 22 2020
SELL
Open market or private sale
$42,030 $70.05 p/Share
600 Reduced 1.26%
47,005 Common Shares
Mar 06 2020
SELL
Payment of exercise price or tax liability
$82,276 $52.64 p/Share
1,563 Reduced 3.18%
47,605 Common Shares
Mar 05 2020
BUY
Exercise of conversion of derivative security
-
3,333 Added 6.35%
49,168 Common Shares
Aug 02 2019
SELL
Payment of exercise price or tax liability
$763,907 $52.56 p/Share
14,534 Reduced 24.08%
45,835 Common Shares
Aug 01 2019
BUY
Exercise of conversion of derivative security
-
37,500 Added 38.32%
60,369 Common Shares
Mar 05 2019
BUY
Grant, award, or other acquisition
$408,700 $40.87 p/Share
10,000 Added 23.33%
32,869 Restricted Stock Units
Aug 02 2018
SELL
Payment of exercise price or tax liability
$708,579 $48.43 p/Share
14,631 Reduced 39.02%
22,869 Common Shares
Aug 01 2018
BUY
Exercise of conversion of derivative security
-
37,500 Added 50.0%
37,500 Common Shares

Also insider at

ITOS
iTeos Therapeutics, Inc. Healthcare
TWH

Tony W Ho

Executive VP, Head of R&D
Cambridge, MA

Track Institutional and Insider Activities on CRSP

Follow CRISPR Therapeutics AG and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRSP shares.

Notify only if

Insider Trading

Get notified when an Crispr Therapeutics Ag insider buys or sells CRSP shares.

Notify only if

News

Receive news related to CRISPR Therapeutics AG

Track Activities on CRSP